Voyager Therapeutics received FDA IND clearance for VY-1706, an investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease. The company’s IND path indicates movement from preclinical readiness into formal clinical development. VY-1706 is designed to address tau biology associated with neurodegeneration, using a gene therapy approach intended to modulate harmful tau species both within and outside neurons. Voyager’s next steps will include initiating or advancing early clinical studies under the newly cleared IND. The FDA’s IND clearance is an important procedural milestone that can shape development timelines and inform investor and partner expectations for the program.